SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes
SGLT2 inhibitors and GLP-1RAs both improve heart failure outcomes
This network meta-analysis of 13,886 patients with type 2 diabetes and heart failure found that both SGLT-2is and GLP-1RAs significantly red…
New data shows both SGLT2 inhibitors and GLP-1RAs effectively reduce heart failure risks for people with type 2 diabetes.
Impact of Antidiabetic Medications on Survival Outcomes in Patients with Cancer
Metformin use linked to lower death rates in cancer patients
A large-scale meta-analysis reveals significant differences in mortality risks between metformin, insulin, and SGLT2 inhibitors in cancer pa…
A large study of over one million patients suggests that the common diabetes drug metformin may help lower mortality rates for those with ca…
Oral semaglutide shows specific MACE and coronary revascularization benefits in patients with type 2 diabetes
Oral semaglutide shows specific heart benefits for type 2 diabetes
This meta-analysis of 67,679 patients evaluated cardiovascular outcomes for oral semaglutide and DPP-4 inhibitors in type 2 diabetes. While …
New data shows oral semaglutide may reduce major heart events and procedures for people with type 2 diabetes, unlike other similar drugs.
Antidiabetic drugs and gut microbiota interact to influence treatment efficacy and tolerability in metabolic syndrome
Gut bacteria may influence how well diabetes drugs work
This narrative review explores how gut microbiota dysbiosis contributes to metabolic syndrome and type 2 diabetes. It synthesizes evidence t…
Your gut bacteria might be the secret reason why some people respond better to diabetes medications than others.
Evaluating Glycemic Control and Weight Reduction of SGLT2 Inhibitors Versus DPP-4 Inhibitors
High dose SGLT2 inhibitors show better blood sugar control
High-dose SGLT2 inhibitors demonstrate superior glycemic control and significant weight reduction compared to DPP-4 inhibitors in type 2 dia…
High-dose SGLT2 inhibitors may offer better blood sugar control and weight loss for people with type 2 diabetes compared to DPP-4 inhibitors…
SGLT2 inhibitors significantly reduce dementia risk in patients with type 2 diabetes
Diabetes drugs may lower dementia risk, study finds
This network meta-analysis involving 845,433 participants analyzed the impact of SGLT2 inhibitors on dementia outcomes in patients with type…
A large analysis of over 845,000 people with type 2 diabetes found that certain diabetes drugs, especially empagliflozin, were linked to a l…
DPP-4 inhibitors may reduce drug-resistant epilepsy risk via the gut microbiota and GLP-1 axis
DPP-4 Inhibitors May Offer New Hope for Drug-Resistant Epilepsy
This systematic review explores how DPP-4 inhibitors might mitigate drug-resistant epilepsy through a hypothesized gut microbiota-SCFA-GLP-1…
New research explores how a common class of medications might protect the brain and improve gut health in patients with drug-resistant epile…
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
Triple oral therapy with metformin, SGLT-2, and DPP-4 inhibitors lowers HbA1c better than dual regimens in adults with type 2 diabetes
Triple oral diabetes drugs lower blood sugar better than two-drug regimens
A systematic review and meta-analysis of 2,606 adults with type 2 diabetes found that triple oral therapy combining metformin, an SGLT-2 inh…
A large analysis shows that taking three specific oral diabetes medicines together lowers blood sugar more effectively than taking just two …
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
All DPP-4 inhibitors Articles
- SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes
- Impact of Antidiabetic Medications on Survival Outcomes in Patients with Cancer
- Oral semaglutide shows specific MACE and coronary revascularization benefits in patients with type 2 diabetes
- Antidiabetic drugs and gut microbiota interact to influence treatment efficacy and tolerability in metabolic syndrome
- Evaluating Glycemic Control and Weight Reduction of SGLT2 Inhibitors Versus DPP-4 Inhibitors
- SGLT2 inhibitors significantly reduce dementia risk in patients with type 2 diabetes
- DPP-4 inhibitors may reduce drug-resistant epilepsy risk via the gut microbiota and GLP-1 axis
- GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
- Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
- Triple oral therapy with metformin, SGLT-2, and DPP-4 inhibitors lowers HbA1c better than dual regimens in adults with type 2 diabetes
- Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
- Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
- Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
- Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD